ClinicalTrials.Veeva

Menu

Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response

R

Reproductive & Genetic Hospital of CITIC-Xiangya

Status

Unknown

Conditions

Infertility,Female

Treatments

Drug: rLH

Study type

Interventional

Funder types

Other

Identifiers

NCT04178135
P2019005

Details and patient eligibility

About

A randomized, controlled, pilot study, for Patients ≥ 35 years and < 40 years old with sufficient ovarian reserve parameters (AFC≥ 5), but showed an unexpected poor or suboptimal ovarian response(defined as ≤ 9 retrieved oocytes in previous full-stimulation cycle, but not get live birth after all embryos were used ). In order to get better oocyte number and quality in the new COS cycle, we will compare LH supplementation from beginning with from middle of stimulation in GnRH-a long protocol.

Enrollment

100 estimated patients

Sex

Female

Ages

35 months to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

1.Infertile women, 35≤ Age< 40 years 2.18<BMI<28 Kg/m2 3.5 ≤AFC ≤20 4.Basal serum FSH≤10 IU/L, E2<70 pg/ml 5.Previous cycle as the first COS cycle,AFC ≥ 5,starting dose of FSH between 150 IU and 300IU with the possibility of adding r-hLH or hMG later in the cycle, number of oocytes retrieved ≤9 (4-9 oocytes retrieval as suboptimal responder and <4 oocytes retrieval as unexpected poor responder), but not get live birth after all embryos were used.

6.Normal uterus and at least one side of the normal ovary 7.GnRH-a long protocol, using Gonal-F® 300IU and Luveris® 150IU for COS 8.Informed consent form signed 9.Willing to follow the study protocol, and able to complete this study

Exclusion criteria

  1. Moderate and Severe endometriosis
  2. PCOS
  3. Previous ovarian surgery history
  4. History of recurrent miscarriages (>2 times of miscarriages)
  5. Any major systemic disease that as per Investigator's discretion precludes subject for participation in the study
  6. With pregnancy contraindications Alcoholism, drug abuse, drug addiction or patients with uncured sexually transmitted disease
  7. According to the judgment of the Investigator, any medical condition or any concomitant surgery/medications that would interfere with evaluation of study medications
  8. Simultaneous participation in another clinical study
  9. Plan to use other Gn other than Gonal-F® or Luveris® during COS treatment Thyroid gland disorders

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

rLH supplementation from day 1 of stimulation
Experimental group
Description:
rLH supplementation from day 1 of stimulation
Treatment:
Drug: rLH
Drug: rLH
rLH supplementation from day 6 of stimulation
Active Comparator group
Description:
rLH supplementation from day 6 of stimulation
Treatment:
Drug: rLH
Drug: rLH

Trial contacts and locations

2

Loading...

Central trial contact

Sufen Cai, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems